s:**
- Test MCU overexpression specifically in layer II neurons in healthy vs
Background and Rationale
This falsification experiment investigates the role of mitochondrial calcium uniporter (MCU) overexpression specifically in layer II cortical neurons during neurodegeneration. MCU dysfunction represents a critical convergence point in Alzheimer's disease pathophysiology, where dysregulated mitochondrial calcium homeostasis contributes to synaptic dysfunction and neuronal death. Layer II neurons in the entorhinal cortex are among the first to degenerate in Alzheimer's disease, making them an ideal target for mechanistic studies. This experiment will utilize viral-mediated MCU overexpression in genetically defined layer II neurons in both healthy wild-type mice and transgenic Alzheimer's disease models (5xFAD or APP/PS1). The study aims to determine whether MCU overexpression is sufficient to induce neurodegeneration in healthy neurons or exacerbate existing pathology in disease models. Advanced imaging techniques including two-photon microscopy will monitor mitochondrial calcium dynamics, while electrophysiology will assess synaptic function. Histological analysis will quantify neuronal survival, tau phosphorylation, and amyloid pathology. This targeted approach will provide crucial insights into whether MCU represents a viable therapeutic target for neuroprotection or if its modulation might paradoxically worsen neurodegeneration.
This experiment directly tests predictions arising from the following hypotheses:
- Mitochondrial Calcium Buffering Enhancement via MCU Modulation
- Mitochondrial Transfer Pathway Enhancement
- Near-infrared light therapy stimulates COX4-dependent mitochondrial motility enhancement
- TFAM overexpression creates mitochondrial donor-recipient gradients for directed organelle trafficking
- Designer TRAK1-KIF5 fusion proteins accelerate therapeutic mitochondrial delivery
Experimental Protocol
Phase 1: Animal Preparation and Genotyping (Weeks 1-2)• Obtain 8-week-old wild-type C57BL/6J mice (n=40) and APP/PS1 AD model mice (n=40)
• Perform genotyping via PCR to confirm AD transgene status
• Acclimate animals to housing conditions for 1 week
• Randomly assign to experimental groups: WT+Control AAV (n=20), WT+MCU-AAV (n=20), AD+Control AAV (n=20), AD+MCU-AAV (n=20)
Phase 2: Stereotaxic AAV Injection (Week 3)
• Anesthetize mice with isoflurane (2-3%)
• Position in stereotaxic frame and inject AAV9-CaMKII-MCU or AAV9-CaMKII-GFP (control) into entorhinal cortex layer II
• Coordinates: AP -4.16mm, ML ±4.2mm, DV -2.8mm from bregma
• Inject 1μL viral suspension (1×10^12 vg/mL) at 0.1μL/min using 33-gauge needle
• Allow 2-week recovery for viral expression
Phase 3: Calcium Imaging Preparation (Week 5)
• Inject Fura-2 AM (2μM) or Rhod-2 AM (5μM) calcium indicators via tail vein
• Prepare acute brain slices (300μm thickness) containing entorhinal cortex
• Identify layer II stellate and pyramidal neurons using patch-clamp electrophysiology
• Confirm MCU overexpression via immunofluorescence in subset of slices
Phase 4: Mitochondrial Calcium Measurements (Week 6)
• Perform live calcium imaging using two-photon microscopy (excitation 780nm)
• Record baseline mitochondrial calcium levels using Rhod-2 fluorescence
• Apply glutamate stimulation (100μM, 30 seconds) to induce calcium influx
• Measure calcium recovery kinetics over 10-minute periods
• Record from minimum 15 neurons per animal per neuronal subtype
Phase 5: Calcium Overload Assessment (Week 7)
• Apply FCCP (10μM) to collapse mitochondrial membrane potential
• Measure calcium retention capacity using sequential calcium pulses
• Quantify mitochondrial permeability transition pore opening via calcein-cobalt assay
• Assess cell viability using propidium iodide staining
• Perform Western blot analysis for MCU, NCLX, and VDAC1 expression levels
Expected Outcomes
MCU overexpression increases mitochondrial calcium uptake by 40-60% in both healthy and AD model neurons, measured via Rhod-2 fluorescence intensity changes (p<0.01).
Layer II stellate neurons show 25-35% greater calcium overload susceptibility compared to pyramidal neurons in AD model mice, demonstrated by reduced calcium retention capacity.
AD model neurons exhibit 50-70% impaired calcium recovery kinetics (τ recovery >180 seconds vs <120 seconds in healthy controls) regardless of MCU expression levels.
MCU overexpression paradoxically reduces mitochondrial calcium overload markers by 20-30% in healthy neurons through enhanced calcium buffering capacity.
AD model mice show 2-3 fold increase in mitochondrial permeability transition pore opening frequency compared to healthy controls, with MCU overexpression providing partial protection.
Neuronal subtype-specific differences emerge with pyramidal neurons showing 40% better calcium handling than stellate neurons under both normal and overload conditions.Success Criteria
•
Statistical power achieved with minimum n=15 neurons per group across all experimental conditions with power >0.8 for detecting 25% effect size differences
• MCU overexpression confirmed by >2-fold increase in protein levels via Western blot and immunofluorescence in targeted layer II neurons (p<0.001)
• Calcium imaging data demonstrates clear dose-response relationships with correlation coefficients r>0.7 between MCU expression and calcium handling parameters
• Significant main effects detected for genotype and treatment factors using two-way ANOVA with p<0.05 and effect size η²>0.1
• Cell viability maintained >85% throughout experimental procedures as measured by propidium iodide exclusion and electrophysiological parameters
• Neuronal subtype identification confirmed in >90% of recorded cells through combined morphological and electrophysiological criteria including input resistance and spike adaptation patterns